Vivoryon Therapeutics NV (VVY) - Total Liabilities

Latest as of December 2025: €2.79 Million EUR ≈ $3.26 Million USD

Based on the latest financial reports, Vivoryon Therapeutics NV (VVY) has total liabilities worth €2.79 Million EUR (≈ $3.26 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Vivoryon Therapeutics NV growing its equity to track the company's year-over-year net asset growth rate.

Vivoryon Therapeutics NV - Total Liabilities Trend (2010–2025)

This chart illustrates how Vivoryon Therapeutics NV's total liabilities have evolved over time, based on quarterly financial data.

Vivoryon Therapeutics NV Competitors by Total Liabilities

The table below lists competitors of Vivoryon Therapeutics NV ranked by their total liabilities.

Company	Country	Total Liabilities
RTA Laboratuvarlari Biyolojik IS:RTALB	Turkey	TL103.51 Million
Domiki Kritis S.A. AT:DOMIK	Greece	€15.20 Million
Widodo Makmur Perkasa PT JK:WMPP	Indonesia	Rp4.06 Trillion
Widodo Makmur Unggas Tbk PT JK:WMUU	Indonesia	Rp1.56 Trillion
Omesti Bhd KLSE:9008	Malaysia	RM74.50 Million
Harn Engineering Solutions Public Company Limited BK:HARN	Thailand	฿404.70 Million
Petrolia SE OL:PSE	Norway	Nkr20.68 Million
Megawin Technology Co Ltd TWO:3122	Taiwan	NT$252.31 Million

Liability Composition Analysis (2010–2025)

This chart breaks down Vivoryon Therapeutics NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VVY company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	7.68	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.59	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.37	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vivoryon Therapeutics NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vivoryon Therapeutics NV (2010–2025)

The table below shows the annual total liabilities of Vivoryon Therapeutics NV from 2010 to 2025.

Year	Total Liabilities	Change
2025-12-31	€2.79 Million ≈ $3.26 Million	-18.01%
2024-12-31	€3.40 Million ≈ $3.98 Million	-25.14%
2023-12-31	€4.55 Million ≈ $5.32 Million	-6.67%
2022-12-31	€4.87 Million ≈ $5.70 Million	-38.82%
2021-12-31	€7.96 Million ≈ $9.31 Million	+125.58%
2020-12-31	€3.53 Million ≈ $4.13 Million	+10.45%
2019-12-31	€3.20 Million ≈ $3.74 Million	+113313.77%
2018-12-31	€2.82K ≈ $3.29K	+53.24%
2017-12-31	€1.84K ≈ $2.15K	-69.30%
2016-12-31	€5.99K ≈ $7.00K	+4.48%
2015-12-31	€5.73K ≈ $6.70K	+4.07%
2014-12-31	€5.51K ≈ $6.44K	-99.95%
2013-12-31	€10.60 Million ≈ $12.39 Million	+128.41%
2012-12-31	€4.64 Million ≈ $5.42 Million	+11.86%
2011-12-31	€4.15 Million ≈ $4.85 Million	+11.30%
2010-12-31	€3.73 Million ≈ $4.36 Million	--

About Vivoryon Therapeutics NV

AS:VVY Netherlands Biotechnology

Market Cap

$44.32 Million

€37.91 Million EUR

Market Cap Rank

#22905 Global

#84 in Netherlands

Share Price

€1.28

Change (1 day)

-8.57%

52-Week Range

€1.00 - €1.72

All Time High

€26.50